P. Llorca

发表

Course of residual symptoms according to the duration of euthymia in remitted bipolar patients

P. Llorca, E. Vieta, C. Bonnín, 2016, Acta psychiatrica Scandinavica.

E. Vassos, D. Berardi, A. Richards, 2022 .

Could the inter-individual variability in cocaine-induced psychotic effects influence the development of cocaine addiction? Towards a new pharmacogenetic approach to addictions.

J. Laplanche, V. Bloch, S. Mouly, 2010, Medical hypotheses.

Hallucinations in schizophrenia and Parkinson’s disease: an analysis of sensory modalities involved and the repercussion on patients

R. Jardri, C. Lançon, P. Llorca, 2016, Scientific Reports.

Cigarette smoking and schizophrenia: a specific clinical and therapeutic profile? Results from the FACE-Schizophrenia cohort

M. Leboyer, B. Aouizerate, G. Fond, 2017, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

The impact of parent history of severe mental illness on schizophrenia outcomes: results from the real-world FACE-SZ cohort

B. Aouizerate, F. Berna, C. Lançon, 2022, European Archives of Psychiatry and Clinical Neuroscience.

Precision-medicine findings from the FACE-SZ cohort to develop motivation-enhancing programs in real-world schizophrenia

F. Berna, R. Joober, P. Sunhary de Verville, 2022, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Towards an improved access to psychiatric rehabilitation: availability and effectiveness at 1-year follow-up of psychoeducation, cognitive remediation therapy, cognitive behaviour therapy and social skills training in the FondaMental Advanced Centers of Expertise-Schizophrenia (FACE-SZ) national coh

B. Aouizerate, G. Fond, F. Berna, 2019, European Archives of Psychiatry and Clinical Neuroscience.

Relationships between low-grade peripheral inflammation and psychotropic drugs in schizophrenia: results from the national FACE-SZ cohort

M. Leboyer, B. Aouizerate, G. Fond, 2018, European Archives of Psychiatry and Clinical Neuroscience.

Chronic low-grade peripheral inflammation is associated with ultra resistant schizophrenia. Results from the FACE-SZ cohort

B. Aouizerate, F. Berna, O. Godin, 2018, European Archives of Psychiatry and Clinical Neuroscience.

Predictors of rapid high weight gain in schizophrenia: Longitudinal analysis of the French FACE-SZ cohort.

M. Leboyer, B. Aouizerate, G. Fond, 2017, Journal of psychiatric research.

Nicotine dependence is associated with depression and childhood trauma in smokers with schizophrenia: results from the FACE-SZ dataset

B. Aouizerate, G. Fond, F. Berna, 2017, European Archives of Psychiatry and Clinical Neuroscience.

Childhood trauma, depression and negative symptoms are independently associated with impaired quality of life in schizophrenia. Results from the national FACE-SZ cohort

M. Leboyer, B. Aouizerate, G. Fond, 2017, Schizophrenia Research.

Chronic Peripheral Inflammation is Associated With Cognitive Impairment in Schizophrenia: Results From the Multicentric FACE-SZ Dataset.

B. Aouizerate, G. Fond, F. Berna, 2016, Schizophrenia bulletin.

Validation of a Psycho-Sensory hAllucinations Scale (PSAS) in schizophrenia and Parkinson's disease

C. Lançon, P. Llorca, F. Durif, 2015, Schizophrenia Research.

Hypovitaminosis D is associated with depression and anxiety in schizophrenia: Results from the national FACE-SZ cohort.

M. Leboyer, B. Aouizerate, G. Fond, 2018, Psychiatry Research.

Adherence to treatment guidelines in clinical practice for using electroconvulsive therapy in major depressive episode.

M. Leboyer, B. Aouizerate, T. d'Amato, 2020, Journal of affective disorders.

Adjunctive agents to antipsychotics in schizophrenia: a systematic umbrella review and recommendations for amino acids, hormonal therapies and anti-inflammatory drugs

F. Berna, J. Mallet, D. Misdrahi, 2023, BMJ mental health.

Child maltreatment, migration and risk of first-episode psychosis: results from the multinational EU-GEI study

S. Tosato, J. Sanjuán, D. Berardi, 2022 .

Confirmations, advances and recommendations for the daily care of schizophrenia based on the French national FACE-SZ cohort

M. Leboyer, B. Aouizerate, G. Fond, 2020, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

A National Network of Schizophrenia Expert Centres: an Innovative Tool to Bridge the Research-Practice Gap

M. Leboyer, G. Fond, F. Berna, 2015, European Psychiatry.

Indirect effect of impulsivity on suicide risk through self-esteem and depressive symptoms in a population with treatment-resistant depression: A FACE-DR study.

E. Haffen, D. Bennabi, W. El-Hage, 2023, Journal of affective disorders.

[Current status and management of patients with bipolar disorder in France: the MONTRA survey].

D. Gourion, M. Lukasiewicz, S. Coulomb, 2013, L'Encephale.

An increase in joy after two weeks is more specific of later antidepressant response than a decrease in sadness.

P. Courtet, E. Corruble, F. Bayle, 2015, Journal of affective disorders.

Recommendations of the Schizophrenia Expert Center network for adequate physical activity in real-world schizophrenia (FACE-SZ)

B. Aouizerate, G. Fond, F. Berna, 2022, European Archives of Psychiatry and Clinical Neuroscience.

An Exploration of the Psychometric Properties of the French Version of the Positive and Negative Syndrome Scale

C. Lançon, P. Auquier, P. Llorca, 1999, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

Validity and reliability of the French‐language version of the Positive and Negative Syndrome Scale (PANSS)

C. Lançon, P. Auquier, G. Reine, 1999, Acta psychiatrica Scandinavica.

Factorial structure of the Positive and Negative Syndrome Scale (PANSS): a forced five‐dimensional factor analysis

C. Lançon, P. Auquier, P. Llorca, 1998, Acta psychiatrica Scandinavica.

Schizophrenia polygenic risk score and cannabis use modify psychosis expression in first episode psychosis patients and population controls

Peter B. Jones, R. Murray, E. Vassos, 2019 .

Neuropsychological assessment fails to predict relapse among cigarette smokers: A prospective study of neurocognitive abilities.

V. Flaudias, A. Schmitt, Marie Christine Picot, 2023, Addictive behaviors.

Psychometric Assessment of an Item Bank for Adaptive Testing on Patient-Reported Experience of Care Environment for Severe Mental Illness: Validation Study

X. Zendjidjian, G. Fond, D. Misdrahi, 2023, JMIR mental health.

French Society for Biological Psychiatry and Neuropsychopharmacology (AFPBN) guidelines for the management of patients with partially responsive depression and treatment-resistant depression: Update 2024.

D. Bennabi, T. Charpeaud, L. Boudieu, 2024, L'Encephale.

Major depression, sleep, hostility and body mass index are associated with impaired quality of life in schizophrenia. Results from the FACE-SZ cohort.

M. Leboyer, B. Aouizerate, G. Fond, 2020, Journal of affective disorders.

Sexual dysfunctions are associated with major depression, chronic inflammation and anticholinergic consumption in the real-world schizophrenia FACE-SZ national cohort

M. Leboyer, B. Aouizerate, G. Fond, 2019, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

How is tailored implementation undertaken using a self-guided toolkit? Qualitative study of the ItFits-toolkit in the ImpleMentAll project

P. Batterham, H. Riper, A. Calear, 2024, Implementation science : IS.

Poverty and inequality in real-world schizophrenia: a national study

F. Berna, S. Leignier, J. Mallet, 2023, Frontiers in public health.

Call for action to address premature mortality due to physical illness in individuals with severe mental disorders

G. Fond, P. Llorca, Laurent Boyer, 2024, Acta psychiatrica Scandinavica.

Variation of subclinical psychosis across 16 sites in Europe and Brazil: findings from the multi-national EU-GEI study.

E. Vassos, S. Tosato, A. Richards, 2024, Psychological medicine.

Clinical and cognitive characteristics of subjects with schizophrenia and childhood attention-deficit/hyperactivity disorder: Results from the multicentric FACE-SZ cross-sectional dataset

D. Capdevielle, I. Chéreau, N. Coulon, 2023, Schizophrenia Research.

THERAPIES HEADING

P. Llorca, Luc Zimmer, 2021 .

Evaluating the efficacy and safety of the currently available once-every-two months long-acting injectable formulations of aripiprazole for the treatment of schizophrenia or as a maintenance monotherapy for bipolar I disorder in adults

L. Samalin, L. Boudieu, P. Llorca, 2024, Expert review of neurotherapeutics.

Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression.

J. Buyze, A. Reif, A. Oliveira-Maia, 2023, The New England journal of medicine.